國家衛生研究院 NHRI:Item 3990099045/15392
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856780      線上人數 : 897
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15392


    題名: In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species
    作者: Tan, MC;Huang, YC;Chen, PJ;Huang, WC;Hsu, SY;Wang, HY;Liou, CH;Sun, JR;Lauderdale, TY;Kuo, SC
    貢獻者: National Institute of Infectious Diseases and Vaccinology;Institute of Population Health Sciences
    摘要: Sir,Elizabethkingia species are increasingly prevalent pathogens, particularly in Asia, and are considered intrinsically resistant to almost all β-lactams.1 However, piperacillin/tazobactam susceptibility testing is performed frequently in clinical laboratories and reported in the literature,1 and piperacillin/tazobactam is used to treat infections caused by susceptible Elizabethkingia strains.2 Herein, we question the practice of routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia spp. due to variability of broth microdilution (BMD) results read by different laboratorians, discordant results of various susceptibility assays, discrepancy between MICs versus MBC or in vivo efficacy and intrinsic resistance evidenced by knockout experiments. One-hundred and eight Elizabethkingia isolates from our previous nationwide studies (Supplementary Methods, available as Supplementary data at JAC Online)3 frequently demonstrated trailing with faint button or turbidity above 4–8 mg/L in BMD testing of piperacillin/tazobactam susceptibility, thus impeding reading (Figure S1). Trailing was also observed in BMD testing of ceftazidime but at a higher concentration (≥64 mg/L). BMD MIC results of piperacillin/tazobactam read by four experienced staff from separate microbiological laboratories varied greatly. Concordance (defined by all four results falling within a 2-fold range) was only 47.2% (51/108, Figure S2); poor concordance was observed both in Elizabethkingia anophelis (45.6%, 41/90) and other Elizabethkingia spp. (55.6%, 10/18). These results may explain the high variability of piperacillin/tazobactam susceptibility rates reported in the literature, which range from 5% to 100% even when obtained from the same BMD platform (piperacillin/tazobactam susceptibility from 5% to 92.4%).
    日期: 2024-01
    關聯: Journal of Antimicrobial Chemotherapy. 2024 Jan 3;79(1):200-202
    Link to: http://dx.doi.org/10.1093/jac/dkad322
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0305-7453&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001085659600001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85181588681
    顯示於類別:[郭書辰] 期刊論文
    [楊采菱] 期刊論文
    [黃盈綺] 期刊論文
    [其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB37850648.pdf256KbAdobe PDF109檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋